Individualization of adjuvant therapy: who can I refuse?



The implementation of adjuvant antitumor drug therapy, covering all patients who are prescribed this type of treatment according to a set of formal group criteria, provides a benefit for a separate category of patients, unjustifiably subjecting to therapy those who are cured and do not need this treatment, as well as a cohort of patients progressing against the background of adjuvant drug therapy. This article highlights the problems of uncertainty in the analysis of the potential benefits and harms of adjuvant therapy, as well as provides an overview of current research studying the use of molecular methods for deeper risk stratification and determining indications for adjuvant treatment in localized forms of malignant tumors.